The Japanese company is to hand across $3bn to Roivant for various subsidiaries that hold an eclectic portfolio of assets.
Deal is the fifth largest robotics surgery purchase ever, and the second big move from Stryker.
Having succeeded with cystic fibrosis Vertex is now chasing a cure for type 1 diabetes.
Spending $250m on Modis gives Zogenix a new rare disease niche, but the timing and the target both look odd.
Ablation company takes on a new tech, and responsibility for an expensive clinical trial.
Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?
Vascular robotics is growing fast and Corindus is the leader here, but Healthineers will need an aggressive sales plan.
Bayer has responded to its current woes by going all in on cell therapy – a move that, even if successful, will take a long time to pay off.
As J&J tears up a licensing deal with Alligator, CD40 agonism might join the likes of Ox40 and IDO as an immuno-oncology approach that has failed to deliver.